What Dufaston Treats: Main Uses and Benefits

Dufaston is commonly used across domains where additional symptomatic support is needed, providing support that helps ease the overall symptom burden in women's health. The therapeutic context of the product is aligned with recognized indications spanning several contexts where symptoms create noticeable physiological strain.

Symptom Management and Cycle Stability

This medication is relevant for managing symptoms that interfere with daily comfort related to conditions such as painful periods (dysmenorrhea), premenstrual syndrome (PMS), endometriosis, and abnormal uterine bleeding. It is also applied in conditions involving episodic or fluctuating manifestations like secondary amenorrhea.

It is used for managing symptom clusters that may become intense or disruptive, and may assist with functional stability during challenging episodes.

Supportive Clinical Scenarios

It is generally applied in clinical settings that involve threatened or habitual miscarriage and may be a component of Hormone Replacement Therapy (HRT). It supports patients during difficult episodes by easing discomfort and is commonly used when short-term symptomatic assistance is needed.

---

Quick Fact: Relevant for Easing Symptom Fluctuations

Regulatory References

1. Dutch/European Medicines Information Bank

Who Can and Cannot Use Dufaston? Regulations and Eligibility

Eligibility for Dufaston (Dydrogesterone) is strictly defined by regulatory documents, focusing on patient population and pre-existing health conditions. Use is primarily established for adult women.

Absolute Contraindications (Must Not Use)

Classification	Condition or Population Prohibited (as per label)
Malignancy Risk	Known or suspected sex hormone-dependent tumours (e.g., meningioma).
Diagnostic Requirement	Undiagnosed vaginal bleeding (etiology must be clarified before use).
Systemic Risk	Hypersensitivity to Dydrogesterone or any of the tablet's excipients.

Restricted and Conditional Use

Population / Condition	Regulatory Status
Severe Hepatic Disease	Contraindicated until liver function values have returned to normal.
Adolescents	Safety and efficacy have not been established (use is not recommended).
Pregnancy	Permitted only for labeled indications (e.g., threatened/habitual miscarriage), requiring careful monitoring.
Breastfeeding	Use is not recommended; it is not known whether the substance is excreted in breast milk.
HRT Use	Must adhere to all contraindications of the concurrent oestrogen preparation.

Patients with rare hereditary disorders such as galactose intolerance or Lapp lactase deficiency should also not take this medicine.

Interactions with other medicines and products

The official interaction profile for Dydrogesterone is defined primarily by its metabolic processing in the liver.

Metabolic Enzyme Interactions

The most documented class of interactions involves substances that are inducers of cytochrome P450 isoenzymes, particularly CYP3A4, which is responsible for Dydrogesterone's metabolism. Co-administration with these inducers accelerates the drug's breakdown, a process that is officially stated to lead to a reduction in systemic exposure and may result in changes in the bleeding pattern. Medicines known to act as inducers include certain anticonvulsants (such as Phenytoin and Carbamazepine) and select anti-infectives (including Rifampicin and Rifabutin). Certain herbal products, notably St. John's Wort (Hypericum perforatum), are also classified as enzyme inducers with the same potential for reduced effect. Conversely, some strong inhibitors, such as Abametapir, may increase Dydrogesterone's serum concentration.

Co-administration Restrictions and Outcomes

A critical restriction applies when Dydrogesterone is used in combined Hormone Replacement Therapy (HRT): the formal contraindications that apply to the co-administered estrogen component must be observed. Furthermore, regulatory information notes a potential pharmacodynamic interaction where Dydrogesterone may diminish the therapeutic activity of oral anticoagulant agents. No specific mandatory dose separation requirements or population-specific cautions related to drug-drug interaction severity are documented in the labeling.

Mechanism of Action: Dydrogesterone

Dufaston (Dydrogesterone) is a unique, orally active progestogen which acts on progesterone receptors in the reproductive system.

It is a stereoisomer of natural progesterone and exhibits a high affinity for the progesterone receptor (PR) but does not exhibit significant binding to androgen, glucocorticoid, or mineralocorticoid receptors.

Its primary action involves the activation of progesterone receptors (PR), inducing secretory transformation of the proliferative endometrium.

Dydrogesterone's primary metabolite, 20alpha-dihydrodydrogesterone, also contributes to the drug's activity by binding to the progesterone receptor (PR).

This process modulates gene transcription in target cells and is an effect mediated solely via the progesterone receptor.

How to Use Dufaston

Dufaston is prescribed as an oral medication in the form of a 10 mg film-coated tablet, which establishes its singular route of administration. The tablet is intended to be swallowed whole with water. If the tablet is scored, the purpose is solely to aid swallowing, not to divide the 10 mg dose into equal, smaller amounts.

---

Dosing and Frequency Patterns

Administration is structured by specific treatment cycles and not taken continuously for most uses. The daily dosage ranges from 10 mg to 30 mg, depending on the specific condition being addressed.

Usage Context	Typical Dosing Schedule	Dosing Pattern
Cycle Regulation / HRT	10 mg once daily	Typically cyclic (e.g., Day 11 to Day 25)
Endometriosis / Dysmenorrhoea	10 mg to 30 mg daily	Divided doses, taken evenly throughout the day
Threatened Miscarriage (Acute)	40 mg initial dose, then 10 mg every 8 hours	Short-term, high-dose initiation followed by reduction

If the total prescribed daily amount is greater than 10 mg, the dose is to be administered in divided doses, spread evenly over the course of the day.

---

Administration Rules and Duration

For conditions requiring specific hormonal preparation (such as Secondary Amenorrhoea or Hormone Replacement Therapy), the use of Dydrogesterone must be given in sequence with concurrent estrogen. The length of treatment is fixed by the prescribing guidelines; for example, treatment for habitual miscarriage is generally continued up to the 20th week of pregnancy.

If a dose is missed, it should be taken within 12 hours of the scheduled time. If the time since the missed dose exceeds 12 hours, the dose must be skipped entirely, and the regular schedule should be resumed. The safety and efficacy of use in adolescents aged 12 to 18 years have not been established.

Dufaston: Recent Clinical Evidence

Evidence for Use in Pregnancy Support: Threatened and Habitual Miscarriage

Clinical research, including controlled trials and meta-analyses, was studied for use in research exploring threatened or habitual miscarriage. Researchers examined this medication in pregnant women, monitoring Live Birth Rate and the rate of continued pregnancy. Research and systematic reviews described measurements related to the frequency of live births, though findings were mixed or varied across studies. The long-term maternal or neonatal outcomes following this intervention are not fully established.

---

Evidence for Use in Endometriosis and Related Pain

Clinical trials and observational studies have explored the use of dydrogesterone in research exploring endometriosis symptoms, which involves periods of heightened symptoms. Researchers focused on patient-reported outcomes describing perceived discomfort, such as changes in pain severity for dysmenorrhea and chronic pelvic pain. Research also monitored measurements related to the size of endometriotic lesions. Rigorous, direct comparative trials against other treatments are not abundant in the published literature, and long-term durability of any observed response is not fully established.

---

Evidence for Use in Menstrual Irregularities and Cycle Stability

Research for dydrogesterone was studied for systemic or functional imbalance related to cycle stability and abnormal uterine bleeding. Evidence is built on clinical evaluation reports and post-marketing observational studies. The core outcome examined was the achievement of a regularized menstrual cycle. Research described patterns related to cycle regularity measurements that were observed during the treatment period. Head-to-head trials against newer hormonal therapies are limited, and research on outcomes related to functional imbalance after treatment is discontinued is not the primary focus.

---

Limitations and Unanswered Research Questions

The evidence base contains limitations noted in systematic reviews, including the reliance on older trials where sample sizes were modest and the evidence quality varies across studies. Furthermore, comparative evidence is lacking in some areas, and the findings were mixed across studies for key endpoints. This means that while studies help show what has been observed so far, there are still unanswered research questions regarding the long-term profile.

Common questions about Dufaston (FAQ)

---

Q: What conditions, other than pregnancy support, is Dufaston prescribed for?

Regulatory documents list several official uses for the medication beyond pregnancy support. These indications include addressing menstrual disorders such as secondary amenorrhoea and dysmenorrhoea (painful periods). It is also officially indicated for treating endometriosis, addressing infertility related to luteal insufficiency, and is used as a cyclical supplement to oestrogen therapy.

---

Q: What is the function of Dufaston when used for luteal phase support (LPS)?

According to official product information, Dufaston is indicated for the support of the luteal phase (LPS) as part of an Assisted Reproductive Technology (ART) procedure. Its function in this context is to provide progesterone support to the uterine lining, consistent with its mechanism of action.

---

Q: Are there any specific medical conditions that prevent a person from using Dufaston?

Official safety information defines several conditions that prohibit the use of Dufaston. These absolute contraindications include known hypersensitivity to the drug's components and any undiagnosed vaginal bleeding. The medication is also contraindicated for use in patients with known or suspected sex hormone-dependent tumours.

---

Q: What types of herbal supplements might interact with Dufaston?

Regulatory documents identify certain herbal products as having the potential to interact with the medication. These are supplements that act as enzyme inducers of CYP3A4, notably St. John's Wort (Hypericum perforatum). Co-administration with these enzyme-inducing supplements may increase the drug's metabolism, which may reduce its concentration in the body.

---

Q: Can Dufaston be used in combination with other hormone replacement therapies?

The medication is designed for use in sequence with a concurrent oestrogen preparation as part of Hormone Replacement Therapy (HRT). This combination requires following the official contraindications and warnings associated with the oestrogen preparation as well.

---

Q: Does Dufaston affect blood pressure levels?

Official warnings state that a marked increase in blood pressure is a disorder that requires medical evaluation and may lead to stopping treatment. This applies especially if the disorder occurs or worsens after starting the medication.

---

Q: Are changes in mood or feelings of depression known to be related to Dufaston use?

The official safety profile has included depression and mood swings among the reported adverse effects.

---

Q: Are there any known long-term side effects associated with Dufaston use?

The safety profile includes information on specific rare, but serious, effects. Regulatory documents classify the growth of progestogen-dependent neoplasms (such as meningioma).

---

Q: Do the side effects of Dufaston go away over time?

Official information provides a time-limited pattern for one specific side effect. Regulatory sources note that breakthrough bleeding (metrorrhagia) is more commonly observed during the first months of treatment.

---

Q: Is the use of Dufaston in pregnancy supported by official safety data?

Official prescribing information indicates the drug's use is permitted only for specific labeled indications during pregnancy, such as threatened or habitual miscarriage. Careful monitoring is required when the medication is administered during pregnancy.

---

Q: What is the maximum approved age for taking Dufaston?

Regulatory documents primarily establish the medication’s use for adult women, and safety and efficacy for adolescents (under 18) are not established. Official product information notes that the clinical experience with treating women older than 65 years is limited.

---

Q: Is Dufaston used to treat symptoms of menopause?

The drug is officially indicated as a component of Menopausal Hormone Therapy (HRT). This use is intended to prevent changes in the uterine lining (endometrial changes) in postmenopausal women with an intact uterus.

Storage and Disposal of Dufaston

The official requirements for storing and disposing of Dufaston (dydrogesterone) are defined by regulatory labeling to maintain product stability and safety over its 5-year shelf life.

---

Storage Conditions

Requirement	Official Instruction
Temperature	Store at a temperature not exceeding 30°C and do not freeze.
Protection	Keep in the original blister and outer carton to protect the tablets from light and moisture.
Safety	Must be kept out of the sight and reach of children.

---

Disposal Instructions

Any unused or expired product must be disposed of correctly. Regulatory instructions mandate that Dufaston must not be thrown into wastewater (drains) or with regular household waste. Disposal must follow local or national pharmaceutical waste regulations, often requiring return to a pharmacy.